Virtual Library

Start Your Search

Yuriko Yagi



Author of

  • +

    P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent (ID 255)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P78.14 - The Efficacy and Safety of ICIs in Treating Postoperative Recurrence of NSCLC: Results of Two Hospitals in Japan (ID 1514)

      00:00 - 00:00  |  Presenting Author(s): Yuriko Yagi

      • Abstract
      • Slides

      Introduction

      Immune-checkpoint inhibitors (ICI) can be beneficial for treating postoperative recurrence of non-small cell lung cancer (NSCLC) because they provide companion diagnosis and assess the tumor microenvironment on a large amount of cancerous tissue. The treatment efficacy and immune-related adverse effects (irAEs) of postoperative ICIs are poorly reported. Therefore, we aimed to assess the safety and efficacy of ICIs in treating postoperative NSCLC recurrence using irAEs as a measurement.

      Methods

      We retrospectively reviewed the clinicopathological data of 115 NSCLC patients treated with ICI mono-therapy between January 2016 and August 2019 at Yao Municipal Hospital and Kinki Chuo Chest Medical Center. Nivolumab, pembrolizumab, and atezolizumab were selected based on the guidelines set before starting the ICI therapy. The two primary endpoints were progression-free survival (PFS), defined as the time from beginning ICI to disease progression, and overall response rate (ORR). The secondary endpoint was safety.

      Results

      115 NSCLC patients underwent ICI treatments for postoperative recurrence. The cohort comprised 86 males and 29 females. There were 76 cases of adenocarcinomas, 23 squamous cell carcinomas, 7 pleomorphic carcinomas, 3 adeno-squamous carcinomas, and 6 other types. The ORR was 26.1%, and the disease control rate was 68%. Median PFS was 182.0 days (95% confidence interval [CI] =118.6–245.4). The estimated proportion of patients who were alive and had no disease progression at 1 year was 34.3% (95% CI=24.8-43.9). In the response (complete response + partial response) group, median PFS was not reached. The estimated percentage of patients who were alive and had no disease progression at 2 years was 72.7% (95% CI=54.9-90), and 60.6% (95% CI=34.3-86.7%) at 3 years. Grade 2–5 irAEs occurred in 35.7% of patients. The most commonly occurring ≥Grade 2 irAEs were interstitial lung disease (12.2%), hypothyroidism (5.2%), and diarrhea (4.3%). In multivariate analyses, EGFR mutations and occurrence of irAEs were independent prognostic factors of PFS, while squamous cell carcinoma type and irAEs were independent prognostic factors of OR.

      Conclusion

      ICI therapy for postoperative recurrent NSCLC is potentially beneficial as it demonstrates a durable OR response. To improve the PFS and response rates, it is essential to search for predictive biomarkers using a sufficient volume of surgical specimens. Our findings are significant because they plug the research gap by highlighting the real-world efficacy of ICIs in NSCLC recurrence treatment.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.